A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia

Kissei

Status and phase: Completed; Phase 3

Conditions: Peritoneal Dialysis; Hyperphosphatemia

Treatments: Drug: PA21

Study type: Interventional

Funder types: Industry

Identifiers

NCT01852682

PA1303

Details and patient eligibility

About

The purpose of this study is to investigate efficacy and safety, when administering PA21, in peritoneal dialysis patients having hyperphosphatemia.

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Receiving stable maintenance peritoneal dialysis
• Peritoneal dialysis patients with hyperphosphatemia

Exclusion criteria

• Patients having history of a pronounced brain / cardiovascular disorder
• Patients having severe gastrointestinal disorders
• Patients having severe hepatic disorders

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

PA21

Experimental group

Treatment:

Drug: PA21